Modafinil in treatment of fatigue in multiple sclerosis
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Krupp, L. B. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520460115022 · Cited by 6,172
Hypocretin (orexin) deficiency in human narcolepsy
Nishino, S., Ripley, B., Overeem, S., Lammers, G. J., & Mignot, E. (2000) · The Lancet · doi:10.1016/s0140-6736(99)05582-8 · Cited by 1,776 · cited 1×
“Although the causes underlying narcolepsy are not fully understood, reduced hypocretin secretion was found to be a factor both in animal studies and in humans [24].”
BackgroundThe impact of fatigue on patients with multiple sclerosis
Fisk, J. D., Pontefract, A., Ritvo, P. G., Archibald, C. J., & Murray, T. J. (1994) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100048691 · Cited by 1,025 · cited 1×
“Seventy-five to 90 % of patients with MS report having fatigue, and 50 to 60 % describe it as the worst symptom of their disease [10, 11].”
BackgroundFatigue in multiple sclerosis and its relationship to depression and neurologic disability
Bakshi, R., Shaikh, Z. A., Miletich, R. S., Czarnecki, D., Dmochowski, J., Henschel, K., Janardhan, V, Dubey, N., & Kinkel, P. R. (2000) · Multiple Sclerosis Journal · doi:10.1177/135245850000600308 · Cited by 480 · cited 1×
“It also tends to be associated with other symptoms, such as depression [2, 14, 16] or sexual dysfunction [43].”
BackgroundModafinil as Adjunct Therapy for Daytime Sleepiness in Obstructive Sleep Apnea
PACK, A. I., BLACK, J. E., SCHWARTZ, J. R. L., & MATHESON, J. K. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.9.2103032 · Cited by 324
Fatigue in multiple sclerosis: relationship to depression, disability, and disease pattern
Kroencke, D. C., Lynch, S. G., & Denney, D. R. (2000) · Multiple Sclerosis Journal · doi:10.1177/135245850000600213 · Cited by 253 · cited 1×
“It also tends to be associated with other symptoms, such as depression [2, 14, 16] or sexual dysfunction [43].”
Background
Cited by
Fatigue in neurological disorders
Chaudhuri, A., & Behan, P. O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15794-2 · Cited by 1,297
Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
Modafinil: a review of neurochemical actions and effects on cognition
Minzenberg, M. J., & Carter, C. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301534 · Cited by 713
Practice Parameters for the Treatment of Narcolepsy and other Hypersomnias of Central Origin
Morgenthaler, T. I., Kapur, V. K., Brown, T. M., Swick, T. J., Alessi, C., Aurora, R. N., Boehlecke, B., Chesson, A. L., Friedman, L., Maganti, R., et al. (2007) · Sleep · doi:10.1093/sleep/30.12.1705 · Cited by 488
Neuropsychiatric Adverse Effects of Interferon-??: Recognition and Management
Raison, C. L., Demetrashvili, M., Capuron, L., & Miller, A. H. (2005) · CNS Drugs · doi:10.2165/00023210-200519020-00002 · Cited by 483
Metadata
- Authors
- Zifko, U. A., Rupp, M., Schwarz, S., Zipko, H. T., & Maida, E. M.
- Venue
- Journal of Neurology
- Published
- 2002-07-01
- Volume
- 249
- Issue
- 8
- Pages
- 983-987
- ISSN
- 0012-1037 (ISSN-L)
- 0340-5354
- 1432-1459
- OpenAlex
- W1975930259
- Cited by
- 200
- References
- 8
- FWCI
- 8.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.